Therapeutics

Polyplus-transfection^®‘s reagents are used in a growing number of preclinical and clinical trials, making us a worldwide leader with extensive expertise in in vivo delivery of nucleic acids. To support the development of new therapies based on the delivery of nucleic acids, Polyplus-transfection^® supplies reagents manufactured in compliance with applicable European Commission and FDA guidelines for preclinical studies as well as for clinical trials phase I to III.

In addition, Polyplus-transfection^® offers novel classes of modified oligonucleotides available for licensing for a wide range of applications including therapeutic purposes.